FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557950124> ?p ?o ?g. }

• W2557950124 abstract "Abstract Abstract 2396 Background: Despite recent advances in understanding the key molecular mechanisms of leukemogenesis, the outcome for patients with Acute Myeloid Leukemia, particularly with a normal karyotype, remains poor. For this large group of patients, genetic alterations in genes such as FLT3, NPM1, CEBPA, IDH1/2, and DNMT3A provide useful prognostic information. However, risk stratification of this group remains only partially resolved and markers of response that can be therapeutically targeted would likely improve outcome for these patients. GADD45A is a tumor suppressor gene that plays cell-type dependent roles in cellular stress coordinating DNA repair and de-methylation, cell cycle arrest, and pro-apoptotic or pro-survival responses (Cancer Ther. 2009;7:268). Methylation of four discrete CpG residues in the proximal promoter of GADD45A is a hallmark of many solid tumours and has been associated with impaired cell stress signalling and reduced drug response (Cancer Res. 2009;69:1527; Oncogene. 2005;24:2705). In AML, GADD45A expression is broadly down-regulated both in normal karyotype and other cytogenetic classes. Down-regulation of GADD45A in AML has been associated with FLT3-ITD (Leukemia. 2009;23:729) and RUNX1 mutations (Satoh et al, Leukemia. 2011;Epub). For those patients without these mutations, the mechanism of GADD45A down-regulation and its prognostic significance remains unknown. We hypothesised that the promoter of GADD45A is methylated in AML and that this methylation is functionally important in patient response. Methods: Using the Sequenom MassARRAY methodology we screened for methylation of four GADD45A promoter CpG dinucleotides (CpG1–4) previously shown to be associated with silencing of GADD45A in breast and prostate cancer, in a retrospective cohort of 222 AML patients collected at diagnosis from the Royal Adelaide Hospital. We then determined association of CpG methylation with outcome and mutation status in our treated patient cohort of 167 patients. In AML cell lines and in primary patient samples we also determined the response to cytotoxic agents in vitro in the presence and absence of demethylating agents. Results: We observed hypermethylation of the CpG1–4 in the proximal promoter of GADD45A in 93 of 222 (42%) of AML patients and in 6 AML cell lines. In the 167 patients treated with standard induction chemotherapy regimes, 61 patients showed methylation of the GADD45A proximal promoter. Of the four CpG residues, methylation of CpG1 was associated with poor overall and event-free survival, in AML overall (Figure 1A) and in normal karyotype AML (Figure 1B). GADD45A CpG1 methylation was significantly associated with IDH1 and IDH2 mutations (p<0.001), but was not associated with FLT3-ITD or other high risk cytogenetic groups. Multivariate analysis (including age, wcc, FLT3-ITD, IDH1/2) revealed that methylation of GADD45A CpG1 is an independent predictor of poor survival in AML, overall (OS; HR 2.17, p=0.006: EFS; HR 2.43, p=0.001), and in normal karyotype AML (OS; HR 2.86, p=0.014: EFS; 5.25, p<0.001). Additionally, treatment of AML cell lines and patient blasts with decitabine (5-Aza-deoxycitidine) resulted in induction of GADD45A mRNA selectively in samples with GADD45A hyper-methylation, and this was associated with increased sensitivity to daunorubicin. Conclusions: DNA methylation of the GADD45A proximal promoter marks a large percentage AML patients, including those with with IDH1/2 mutations, and is an independent predictor of poor outcome, particularly in AML patients with normal karyotype. Our biological data shows that induction of GADD45A mRNA expression with decitabine in methylated samples is associated with increased response to cytotoxic agents. Thus GADD45A proximal promoter methylation represents a new biomarker that may provide prognostic information in the heterogeneous normal karyotype AML group. Given that recent clinical trials are combining Azacitidine with chemotherapy and other agents for induction therapy in AML (Blood;118:1472), this may represent a marker to help define patients that will benefit from this approach. Disclosures: Wei: Celgene: Research Funding." @default.
• W2557950124 created "2016-12-08" @default.
• W2557950124 creator A5004782158 @default.
• W2557950124 creator A5005591514 @default.
• W2557950124 creator A5008066229 @default.
• W2557950124 creator A5012187421 @default.
• W2557950124 creator A5019089475 @default.
• W2557950124 creator A5034211889 @default.
• W2557950124 creator A5040177912 @default.
• W2557950124 creator A5054325352 @default.
• W2557950124 creator A5061012183 @default.
• W2557950124 creator A5069611762 @default.
• W2557950124 creator A5080144419 @default.
• W2557950124 creator A5085655489 @default.
• W2557950124 date "2012-11-16" @default.
• W2557950124 modified "2023-09-30" @default.
• W2557950124 title "Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival." @default.
• W2557950124 doi "https://doi.org/10.1182/blood.v120.21.2396.2396" @default.
• W2557950124 hasPublicationYear "2012" @default.
• W2557950124 type Work @default.
• W2557950124 sameAs 2557950124 @default.
• W2557950124 citedByCount "0" @default.
• W2557950124 crossrefType "journal-article" @default.
• W2557950124 hasAuthorship W2557950124A5004782158 @default.
• W2557950124 hasAuthorship W2557950124A5005591514 @default.
• W2557950124 hasAuthorship W2557950124A5008066229 @default.
• W2557950124 hasAuthorship W2557950124A5012187421 @default.
• W2557950124 hasAuthorship W2557950124A5019089475 @default.
• W2557950124 hasAuthorship W2557950124A5034211889 @default.
• W2557950124 hasAuthorship W2557950124A5040177912 @default.
• W2557950124 hasAuthorship W2557950124A5054325352 @default.
• W2557950124 hasAuthorship W2557950124A5061012183 @default.
• W2557950124 hasAuthorship W2557950124A5069611762 @default.
• W2557950124 hasAuthorship W2557950124A5080144419 @default.
• W2557950124 hasAuthorship W2557950124A5085655489 @default.
• W2557950124 hasConcept C104317684 @default.
• W2557950124 hasConcept C121608353 @default.
• W2557950124 hasConcept C140173407 @default.
• W2557950124 hasConcept C150194340 @default.
• W2557950124 hasConcept C190727270 @default.
• W2557950124 hasConcept C2483381 @default.
• W2557950124 hasConcept C2778461978 @default.
• W2557950124 hasConcept C2778729363 @default.
• W2557950124 hasConcept C30481170 @default.
• W2557950124 hasConcept C33288867 @default.
• W2557950124 hasConcept C45091340 @default.
• W2557950124 hasConcept C501734568 @default.
• W2557950124 hasConcept C502942594 @default.
• W2557950124 hasConcept C53226629 @default.
• W2557950124 hasConcept C54355233 @default.
• W2557950124 hasConcept C86803240 @default.
• W2557950124 hasConceptScore W2557950124C104317684 @default.
• W2557950124 hasConceptScore W2557950124C121608353 @default.
• W2557950124 hasConceptScore W2557950124C140173407 @default.
• W2557950124 hasConceptScore W2557950124C150194340 @default.
• W2557950124 hasConceptScore W2557950124C190727270 @default.
• W2557950124 hasConceptScore W2557950124C2483381 @default.
• W2557950124 hasConceptScore W2557950124C2778461978 @default.
• W2557950124 hasConceptScore W2557950124C2778729363 @default.
• W2557950124 hasConceptScore W2557950124C30481170 @default.
• W2557950124 hasConceptScore W2557950124C33288867 @default.
• W2557950124 hasConceptScore W2557950124C45091340 @default.
• W2557950124 hasConceptScore W2557950124C501734568 @default.
• W2557950124 hasConceptScore W2557950124C502942594 @default.
• W2557950124 hasConceptScore W2557950124C53226629 @default.
• W2557950124 hasConceptScore W2557950124C54355233 @default.
• W2557950124 hasConceptScore W2557950124C86803240 @default.
• W2557950124 hasLocation W25579501241 @default.
• W2557950124 hasOpenAccess W2557950124 @default.
• W2557950124 hasPrimaryLocation W25579501241 @default.
• W2557950124 hasRelatedWork W1802898611 @default.
• W2557950124 hasRelatedWork W1974798829 @default.
• W2557950124 hasRelatedWork W1994524037 @default.
• W2557950124 hasRelatedWork W2006354293 @default.
• W2557950124 hasRelatedWork W2048348557 @default.
• W2557950124 hasRelatedWork W2071908491 @default.
• W2557950124 hasRelatedWork W2072581855 @default.
• W2557950124 hasRelatedWork W2522815735 @default.
• W2557950124 hasRelatedWork W2531862030 @default.
• W2557950124 hasRelatedWork W2536460698 @default.
• W2557950124 hasRelatedWork W2563720445 @default.
• W2557950124 hasRelatedWork W2569845331 @default.
• W2557950124 hasRelatedWork W2570134144 @default.
• W2557950124 hasRelatedWork W2584285743 @default.
• W2557950124 hasRelatedWork W2585475230 @default.
• W2557950124 hasRelatedWork W2587917060 @default.
• W2557950124 hasRelatedWork W2754864362 @default.
• W2557950124 hasRelatedWork W2992061656 @default.
• W2557950124 hasRelatedWork W3198088351 @default.
• W2557950124 hasRelatedWork W3148196117 @default.
• W2557950124 isParatext "false" @default.
• W2557950124 isRetracted "false" @default.
• W2557950124 magId "2557950124" @default.
• W2557950124 workType "article" @default.